Search results for "expression"

showing 10 items of 5168 documents

Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review

2016

Prostate cancer, the second most frequently diagnosed cancer in males worldwide, is estimated to be diagnosed in 1.1 million men per year. Introduction of PSA testing substantially improved early detection of prostate cancer, however it also led to overdiagnosis and subsequent overtreatment of patients with an indolent disease. Treatment outcome and management of prostate cancer could be improved by the development of non-invasive biomarker assays that aid in increasing the sensitivity and specificity of prostate cancer screening, help to distinguish aggressive from indolent disease and guide therapeutic decisions. Prostate cancer cells release miRNAs into the bloodstream, where they exist …

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyOverdiagnosisDiseaseReviewExosomesManagement of prostate cancer03 medical and health sciencesProstate cancer0302 clinical medicinePredictive Value of TestsInternal medicinemedicineBiomarkers TumorHumansCell-free miRNAsGenetic TestingLiquid biopsyOverdiagnosisProstate cancerLiquid biopsybusiness.industryGene Expression ProfilingCancerDisease ManagementProstatic NeoplasmsBiological TransportExtracellular vesiclesmedicine.diseasePrognosisBody FluidsMicroRNAs030104 developmental biologyProstate cancer screeningOncology030220 oncology & carcinogenesisImmunologyMolecular MedicineBiomarker (medicine)businessTranscriptomeMicrovesiclesBiomarkersMolecular Cancer
researchProduct

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Cl…

2017

AbstractPurpose: This study investigated the safety, clinical activity, and target-associated biomarkers of lumretuzumab, a humanized, glycoengineered, anti-HER3 monoclonal antibody (mAb), in combination with the EGFR-blocking agents erlotinib or cetuximab in patients with advanced HER3-positive carcinomas.Experimental Design: The study included two parts: dose escalation and dose extension phases with lumretuzumab in combination with either cetuximab or erlotinib, respectively. In both parts, patients received lumretuzumab doses from 400 to 2,000 mg plus cetuximab or erlotinib according to standard posology, respectively. The effect of HRG mRNA and HER3 mRNA and protein expression were inv…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyReceptor ErbB-3Neuregulin-1CetuximabPharmacologyAntibodies Monoclonal Humanized03 medical and health sciencesErlotinib Hydrochloride0302 clinical medicineInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansAdverse effectneoplasmsSurvival analysisCetuximabbusiness.industryCancerLumretuzumabmedicine.diseaseSurvival Analysisrespiratory tract diseasesClinical trialGene Expression Regulation Neoplastic030104 developmental biologyTreatment OutcomeOncology030220 oncology & carcinogenesisMonoclonalFemaleErlotinibbusinessmedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

miR‐200c and phospho‐AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis

2016

Lung metastasis is the major cause of death in osteosarcoma patients. However, molecular mechanisms underlying this metastasis remain poorly understood. To identify key molecules related with pulmonary metastasis of pediatric osteosarcomas, we analyzed high-throughput miRNA expression in a cohort of 11 primary tumors and 15 lung metastases. Results were further validated with an independent cohort of 10 primary tumors and 6 metastases. In parallel, we performed immunohistochemical analysis of activated signaling pathways in 36 primary osteosarcomas. Only phospho-AKT associated with lower overall survival in primary tumors, supporting its role in osteosarcoma progression. CTNNB1 expression a…

0301 basic medicineOncologyMaleCancer ResearchmiR‐200cLung NeoplasmsCDH1MetastasisCohort Studies0302 clinical medicineCell MovementPhospho‐AKTPhosphorylationChildOsteosarcomabiologyGeneral MedicineArticlesCadherinsPrognosisPrimary tumorGene Expression Regulation Neoplasticmedicine.anatomical_structureLung metastasisOncology030220 oncology & carcinogenesisDisease ProgressionMolecular MedicineOsteosarcomaFemaleSignal Transductionmedicine.medical_specialtyAdolescentMesenchymal to epithelial transitionArticle03 medical and health sciencesYoung AdultAntigens CDInternal medicineCell Line TumormicroRNAGeneticsmedicineBiomarkers TumorHumansEpithelial–mesenchymal transitionCell ProliferationLungGene Expression ProfilingReproducibility of ResultsEpithelial CellsPediatric osteosarcomamedicine.diseaseSurvival AnalysisEnzyme ActivationMicroRNAs030104 developmental biologyTumor progressionbiology.proteinProto-Oncogene Proteins c-aktMolecular Oncology
researchProduct

Association study of MMP8 gene in osteoarthritis.

2016

Objectives: Osteoarthritis (OA) is a joint disease common in the elderly. There is a prior functional evidence for different matrix metalloproteinases (MMPs), such as MMP8 and MMP9, having a role in the breakdown of cartilage extracellular matrix in OA. Thus, we analyzed whether the common genetic variants of MMP8 and MMP9 contribute to the risk of OA. Materials and methods: In total, 13 common tagging single-nucleotide polymorphisms (SNPs) were studied in a discovery knee OA cohort of 185 cases and 895 controls. For validation, two knee OA replication cohorts and two hand OA replication cohorts were studied (altogether 1369 OA cases, 4445 controls in the five cohorts). The chi(2) test for …

0301 basic medicineOncologyMaleLinkage disequilibriumLINKAGE DISEQUILIBRIUMMATRIX METALLOPROTEINASESOsteoarthritisSUSCEPTIBILITYBioinformaticsMMP8BiochemistryOrthopedics and Sports MedicineIN-VIVOta3141Middle AgedOsteoarthritis Knee3142 Public health care science environmental and occupational healthmedicine.anatomical_structureMatrix Metalloproteinase 8CohortFemaleEXPRESSIONAdultmedicine.medical_specialtySingle-nucleotide polymorphismKNEE OSTEOARTHRITISta3111Polymorphism Single NucleotideAssociationANKLE JOINTS03 medical and health sciencesRheumatologyInternal medicinemedicineSNPHumansgeneMolecular BiologyGeneAgedbusiness.industryCartilageta1184Cell BiologyARTICULAR-CARTILAGEmedicine.diseaseosteoarthritis030104 developmental biologyWIDE STATISTICAL SIGNIFICANCENEUTROPHIL COLLAGENASE3111 BiomedicinebusinessConnective tissue research
researchProduct

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC

2017

[EN] Background Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is highly variable and clinical correlations are emerging. Using NSCLC biomaterial and clinical data from the European Thoracic Oncology Platform Lungscape iBiobank, we explore the epidemiology of mutations and association to clinicopathologic features and patient outcome (relapse-free survival, time-to-relapse, overall survival). Methods Clinically annotated, resected stage I¿III NSCLC FFPE tissue was assessed for gene mutation using a microfluidics-based multiplex PCR platform. Mutant-allele detection sensitivity is¿>1% for most of the ~150 (13 genes) mutations covered in the multiplex test.…

0301 basic medicineOncologyMaleLung NeoplasmsDNA Mutational AnalysisKRAS MUTATIONSGene mutationmedicine.disease_cause0302 clinical medicinemultiplex mutation analysisCarcinoma Non-Small-Cell LungMultiplex mutation analysisPrevalenceMultiplexAnaplastic Lymphoma KinaseHETEROGENEITYAged 80 and overMutationSmokingHematologyMiddle AgedProto-Oncogene Proteins c-metProgression-Free SurvivalOncology030220 oncology & carcinogenesisAdenocarcinomaFemaleKRASPREDICT SURVIVALAdultmedicine.medical_specialtyEGFRCELL LUNG-CANCERPrognosis molecular stagingprognosis molecular stagingEGFR KRAS PIK3CAVALIDATION03 medical and health sciencesYoung AdultInternal medicineMultiplex polymerase chain reactionmedicineKRASTYROSINE KINASE INHIBITORSHumansProgression-free survivalLung cancerAgedNeoplasm Stagingbusiness.industryMICROBIOLOGIAADENOCARCINOMAAMPLIFICATIONPIK3CAmedicine.disease030104 developmental biologynon-small-cell lung cancerMutationOVEREXPRESSIONbusinessMultiplex Polymerase Chain ReactionNon-small-cell lung cancerAnnals of Oncology
researchProduct

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue

2018

Abstract Background Gene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL), but the routinely adoption of prognostic stromal signatures remains limited. Patients and methods Here, we applied the computational method CIBERSORT to generate a 1028-gene matrix incorporating signatures of 17 immune and stromal cytotypes. Then, we carried out a deconvolution on publicly available GEP data of 482 untreated DLBCLs to reveal associations between clinical outcomes and proportions of putative tumor-infiltrating cell types. Forty-five genes related to peculiar prognostic cytotypes were selected and their expression …

0301 basic medicineOncologyMalePathologyHematologic MalignanciesBiopsyDatasets as TopicPredictive Value of TestDeconvolutionCohort StudiesTranscriptomeAntibodies Monoclonal Murine-Derived0302 clinical medicineprognosticatorsimmune system diseaseshemic and lymphatic diseasesTumor MicroenvironmentCluster Analysisdigital expression analysisRandomized Controlled Trials as TopicParaffin EmbeddingHematology; OncologyHematologyMiddle AgedPrognosisCorrigendaProgression-Free SurvivalAlgorithmOncology030220 oncology & carcinogenesisCell-of-originFemaleLymphoma Large B-Cell DiffuseSurvival AnalysiAlgorithmsHumanAdultmedicine.medical_specialtyStromal cellMicroenvironmentFormalin fixed paraffin embeddedPrognosiReproducibility of ResultDissection (medical)03 medical and health sciencesDigital expression analysiYoung AdultPrognosticatorPredictive Value of TestsFormaldehydeInternal medicinemedicineHumansProgression-free survivalGeneSurvival analysisAgedTumor microenvironmentCluster AnalysiProportional hazards modelbusiness.industryGene Expression ProfilingReproducibility of ResultsComputational BiologyOriginal Articlesmedicine.diseaseSurvival AnalysisGene expression profiling030104 developmental biologyDLBCLCohort StudieTranscriptomebusinessDiffuse large B-cell lymphomaDLBCL microenvironment deconvolution cell-of-origin digital expression analysis prognosticators
researchProduct

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

2016

// Aurelie Bertaut 1 , Caroline Truntzer 2 , Rachid Madkouri 3 , Coureche Guillaume Kaderbhai 4 , Valentin Derangere 5 , Julie Vincent 4 , Bruno Chauffert 6 , Marie Helene Aubriot-Lorton 7 , Wahlid Farah 3 , Klaus Luc Mourier 3 , Romain Boidot 5,8 and Francois Ghiringhelli 4,5,8,9 1 Biostatistics unit Georges Francois Leclerc Cancer Center, Dijon, France 2 CLIPP, Research Center, University of Burgundy, Dijon, France 3 Department of Neurosurgery, CHU, Dijon, France 4 Department of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon, France 5 Platform of Transfer in Cancer Biology Genetic and histology, Georges Francois Leclerc Cancer Center, Dijon, France 6 Department of Medical…

0301 basic medicineOncologyMaleVascular Endothelial Growth Factor Agenetic structuresNeutrophilsmedicine.medical_treatmentAngiogenesis InhibitorsBiomarkers Pharmacological[ SDV.CAN ] Life Sciences [q-bio]/CancerLeukocyte Count0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorEndothelial Growth-Factorprognostic factorNeoadjuvant therapyRandomized Controlled Trials as TopicNeovascularization PathologicBrain NeoplasmsColony-Stimulating FactorAge FactorsChemoradiotherapyMiddle AgedPrognosisNeoadjuvant Therapy3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisTo-Lymphocyte RatioAbsolute neutrophil countFemalemedicine.drugmedicine.medical_specialtyBevacizumabMalignant Glioma[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologybevacizumabDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPretreatment NeutrophilKarnofsky Performance StatusSingle-Agent BevacizumabRetrospective StudiesNewly-Diagnosed GlioblastomaRecurrent Glioblastomabusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyGene Expression ProfilingglioblastomaCancerRetrospective cohort studyLomustinemedicine.diseasePhase-Ii Trialeye diseasesSurgeryIrinotecan030104 developmental biologyprognosistic factorBrain-Tumorssense organsClinical Research PaperNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

Expression profiles of HMGB1 on B-CLL related leukocytes contribute to prediction of relapse.

2020

The High Mobility Group Box 1 (HMGB1) is a nuclear protein that is frequently overexpressed in hematologic diseases and might be of relevance in immunogenic cancer control thus correlating with patients' (pts.) prognosis in diseases such as acute myeloid, acute lymphatic and chronic lymphocytic leukemia.Expression profiles of blasts from AML (n = 21), ALL (n = 16) and of B-lymphocytes of CLL (n = 9) pts. were analyzed for surface expression of HMGB1 using flow cytometry. Expression was quantified and correlated with clinically and prognostically relevant markers.Expression profiling of HMGB1 in blasts of AML and ALL subtypes did not show differences between primary vs. secondary disease dev…

0301 basic medicineOncologyMalemedicine.medical_specialtyMyeloidChronic lymphocytic leukemiaImmunologyPlasma Cellschemical and pharmacologic phenomenaHMGB1Biomarkers PharmacologicalFlow cytometryDiagnosis Differential03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicineImmunology and AllergyHumansAnthracyclinesNuclear proteinHMGB1 ProteinB-LymphocytesAntibiotics Antineoplasticbiologymedicine.diagnostic_testbusiness.industryRemission InductionAge FactorsHematologyMiddle AgedGender relatedmedicine.diseaseFlow CytometryPrognosisLeukemia Lymphocytic Chronic B-CellGene expression profilingGene Expression Regulation NeoplasticLeukemia Myeloid Acute030104 developmental biologyLymphatic systemmedicine.anatomical_structurebiology.proteinDisease ProgressionFemaleNeoplasm Recurrence Localbusiness030215 immunologyImmunobiology
researchProduct

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene

2016

AbstractA subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators, and their target gene CCNE2 seems to play an important role in resistance to trastuzumab therapy. Cell viability was evaluated in trastuzumab treated HER2+ BT474 wt (sensitive), BT474r (acquired resistance), HCC1954 (innate resistance), and MDA-MB-231 (HER2−) cell lines, and the expression of miR-26a, miR-30b, and their target genes was measured. BT474 wt cell viability decreased by 60% and miR-26a and miR-30b were significantly overexpressed (~3-fold, p = 0.003 and p = 0.002, respectively) after trastuzumab trea…

0301 basic medicineOncologyMama -- Càncer -- Aspectes genèticsmedicine.medical_specialtyCell SurvivalReceptor ErbB-2Down-RegulationMama -- Càncer -- TractamentBreast NeoplasmsDrug resistanceArticle03 medical and health sciences0302 clinical medicineBreast cancerTrastuzumabInternal medicineCell Line TumorCyclinsmedicineGene silencingHumansViability assayGene SilencingReceptorskin and connective tissue diseasesneoplasmsRegulation of gene expressionMultidisciplinarybusiness.industryCell CycleTrastuzumabmedicine.diseaseNeoplasm ProteinsGene Expression Regulation NeoplasticMicroRNAs030104 developmental biologyCell cultureDrug Resistance Neoplasm030220 oncology & carcinogenesisFemalebusinessmedicine.drugScientific Reports
researchProduct

Current molecular and clinical insights into uveal melanoma (Review)

2021

Uveal melanoma (UM) represents the most prominent primary eye cancer in adults. With an incidence of approximately 5 cases per million individuals annually in the United States, UM could be considered a relatively rare cancer. The 90.95% of UM cases arise from the choroid. Diagnosis is based mainly on a clinical examination and ancillary tests, with ocular ultrasonography being of greatest value. Differential diagnosis can prove challenging in the case of indeterminate choroidal lesions and, sometimes, monitoring for documented growth may be the proper approach. Fine needle aspiration biopsy tends to be performed with a prognostic purpose, often in combination with radiotherapy. Gene expres…

0301 basic medicineOncologyUveal NeoplasmsCancer Researchmedicine.medical_specialtydiagnosisEnucleationBiology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansNeoplasm MetastasisGrading (tumors)MelanomaBiomarkers; Diagnosis; Epigenetics; Prognosis; Staging; Treatment; Uveal melanomamedicine.diagnostic_testtreatmentepigeneticsMelanomaGene Expression ProfilingCancerbiomarkersArticlesstagingmedicine.diseasePrognosisPrimary tumor030104 developmental biologyFine-needle aspirationOncology030220 oncology & carcinogenesisMutationDifferential diagnosisuveal melanomaGNAQ
researchProduct